This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Exact Sciences Colon Cancer Screen Results Disappoint Wall Street

Stocks in this article: EXAS

Updated with new information.

MADISON, Wisc. ( TheStreet) -- Exact Sciences (EXAS) is trading lower Thursday on results from a pivotal study of its non-invasive colon cancer screening test. Cologuard's accuracy met the endpoints of the pivotal study but not enough to satisfy investors.

Shares of Exact are down 31% to $6.84 in Thursday pre-market trading.

In the study of 10,000 patients at average risk for colon cancer, Cologuard demonstrated 92% sensitivity for the detection of colon cancer and 42% sensitivity for the detection of pre-cancerous lesions. The test achieved a specificity of 87% during the trial, Exact Science said.

Based on these results, Exact Sciences will seek U.S. approval of Cologuard as a new screening test for colon cancer later this year.

Investors, however, were hoping for better accuracy from Cologuard based on prior study results. In particular, the 42% sensitivity for pre-cancerous lesions fell way short of Cologuard's earlier studies in which sensitivities for pre-cancer were in the high 50% to low 60% range. Detection and removal of pre-cancerous lesions can significantly reduce the incidence of colon cancer, similar to what happened to cervical cancer following the introduction of pap smear tests.

On a conference call with investors, Exact Sciences CEO Kevin Conroy acknowledged that Cologuard's ability to detect pre-cancerous lesion fell below the company's expectations but he insisted that the screening test would still be viewed as effective by doctors and insurers.

"We believe these data are powerful," said Conroy.

Investors were also hoping to see specificity closer to 90%; the actual 87% result is seen not coming close enough. Specificity measures the test's ability to accurately detect a negative result. In this case, however, for every 100 patients who don't have cancer or pre-cancerous lesions, Cologuard will come back reading a positive cancer signal. A false-positive rate this high could prove problematic for Exact Sciences, particularly as it tries to market the test to doctors who treat patients at low risk for disease.

Cologuard is a non-invasive screening test for colon cancer and pre-cancerous lesions. Cologuard isolates and identifies cancerous and pre-cancerous DNA from a patient's stool sample. Exact Sciences designed Cologuard to more accurately detect early stage colon cancer and pre-cancerous lesions compared to the existing stool-based screens FOBT and FIT, which can pick up 40-60% of colon cancers but are less accurate in detecting pre-cancerous lesions.

Cologuard isn't necessarily designed to be more accurate than a colonoscopy, but the company believes adoption of the non-invasive and easy-to-use Cologuard will lead to higher colon cancer screening rates. (Half of Americans recommended for colon exams choose not to be tested.) Used ahead of colonoscopy, Cologuard could also improve the detection of pre-cancer and early stage cancer when it is most treatable and curable.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs